- Home
- GELS vs QNTM Comparison
GELS vs QNTM Comparison
Compare GELS & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GELS
- QNTM
- Stock Information
- Founded
- GELS 2018
- QNTM 1998
- Country
- GELS Australia
- QNTM Canada
- Employees
- GELS N/A
- QNTM N/A
- Industry
- GELS
- QNTM
- Sector
- GELS
- QNTM
- Exchange
- GELS NYSE
- QNTM NYSE
- Market Cap
- GELS 8.7M
- QNTM 8.7M
- IPO Year
- GELS 2024
- QNTM N/A
- Fundamental
- Price
- GELS $1.90
- QNTM $7.08
- Analyst Decision
- GELS
- QNTM
- Analyst Count
- GELS 0
- QNTM 0
- Target Price
- GELS N/A
- QNTM N/A
- AVG Volume (30 Days)
- GELS 4.7M
- QNTM 871.0K
- Earning Date
- GELS 02-15-2025
- QNTM 05-06-2025
- Dividend Yield
- GELS N/A
- QNTM N/A
- EPS Growth
- GELS N/A
- QNTM N/A
- EPS
- GELS N/A
- QNTM N/A
- Revenue
- GELS $95,618.00
- QNTM N/A
- Revenue This Year
- GELS N/A
- QNTM N/A
- Revenue Next Year
- GELS N/A
- QNTM N/A
- P/E Ratio
- GELS N/A
- QNTM N/A
- Revenue Growth
- GELS N/A
- QNTM N/A
- 52 Week Low
- GELS $0.77
- QNTM $2.70
- 52 Week High
- GELS $5.50
- QNTM $32.50
- Technical
- Relative Strength Index (RSI)
- GELS N/A
- QNTM 54.60
- Support Level
- GELS N/A
- QNTM $5.91
- Resistance Level
- GELS N/A
- QNTM $6.43
- Average True Range (ATR)
- GELS 0.00
- QNTM 0.70
- MACD
- GELS 0.00
- QNTM -0.02
- Stochastic Oscillator
- GELS 0.00
- QNTM 80.77
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.